Skip to content

Clinical study on the effectiveness and safety of hypothermic mechanical infusion combined with antibiotic in vitro therapy to reduce the risk of donor source infection

Clinical study on the effectiveness and safety of hypothermic mechanical infusion combined with antibiotic in vitro therapy to reduce the risk of donor source infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088150
Enrollment
Unknown
Registered
2024-08-13
Start date
2024-08-14
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supply kidney infection

Interventions

1:Add antibiotics to the organ preservation solution for hypothermic mechanical perfusion before transplantation

Sponsors

Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Brain/heart death patients who have passed the renal function assessment and obtained positive blood cultures within the previous week; (2) Age = 18 years old, = 75 years old; (3) Sign a body organ donation agreement;

Exclusion criteria

Exclusion criteria: (1) Highly toxic pathogen infection, unexplained central nervous system infection, active tuberculosis infection, and multidrug-resistant bacterial infection; Active Candida bacteremia, caused by active infections such as Cryptococcus neoformans, Aspergillus, Mucor, Pneumocystis carinii, and invasive filamentous fungal infections; Parasitic infection, history of HIV infection, tetanus, rabies, invasive or hematological malignancies, uncontrolled or unknown sepsis, severe DIC, sickle cell anemia or other hemoglobinopathies; (2) After comprehensive evaluation such as visual judgment during acquisition, it is deemed unqualified; (3) The pathological evaluation of the supplied kidney is not qualified; (4) Patients whose expected survival time cannot exceed the study period;

Design outcomes

Primary

MeasureTime frame
Infection situation;Recipient prognosis;

Countries

China

Contacts

Public ContactJipin Jiang

Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology

jpjiang@tjh.tjmu.edu.cn+86 177 2056 9827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026